AbbVie Inc (ABBV)vsASML Holding NV ADR (ASML)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
ASML
ASML Holding NV ADR
$1,592.02
+4.97%
TECHNOLOGY · Cap: $595.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 86% more annual revenue ($62.82B vs $33.69B). ASML leads profitability with a 29.7% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ASML
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$201.55
$33.36 premium
Intrinsic value data unavailable for ASML.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 52 in profit
Strong operational efficiency at 36.0%
Keeps 30 of every $100 in revenue as profit
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 1396.5x book value
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : ASML
The strongest argument for ASML centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 29.7% and operating margin at 36.0%. Revenue growth of 13.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : ASML
The primary concerns for ASML are PEG Ratio, P/E Ratio, Price/Book. A P/E of 51.0x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while ASML is a mature play — different risk/reward profiles.
ASML carries more volatility with a beta of 1.37 — expect wider price swings.
ASML is growing revenue faster at 13.2% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 62/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ASML Holding NV ADR
TECHNOLOGY · SEMICONDUCTOR EQUIPMENT & MATERIALS · USA
ASML Holding NV develops, produces, markets, sells and services advanced semiconductor equipment systems consisting of lithography, metrology and inspection related systems for memory and logic chip manufacturers. The company is headquartered in Veldhoven, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?